Antipyretic Drugs for Children Market Report 2026

The antipyretic drugs for children market size has grown strongly in recent years. It will grow from $3.4 billion in 2025 to $3.61 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to high prevalence of childhood infections, widespread use of acetaminophen, hospital pediatric care growth, established dosing guidelines, retail pharmacy expansion.

The antipyretic drugs for children market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in pediatric population, rising self-care practices, expansion of pediatric otc products, increasing healthcare access, improved drug safety labeling. Major trends in the forecast period include rising incidence of pediatric fever cases, growing preference for liquid dosage forms, expansion of otc pediatric medications, increased parental awareness of fever management, higher demand for age-specific formulations.

The increasing prevalence of viral and bacterial infections is expected to drive the growth of the antipyretic drugs for children market in the coming years. Viral infections occur when viruses invade host cells, whereas bacterial infections result from harmful bacteria multiplying within the body. The rise in viral and bacterial infections is attributed to the resurgence of respiratory pathogens following the easing of pandemic restrictions. The antipyretic drugs for children market aids in care management by offering fever-reducing medications that alleviate discomfort and prevent complications during pediatric infections. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, marking a rise of 1,295 cases. Consequently, the growing prevalence of viral and bacterial infections is propelling the growth of the antipyretic drugs for children market.

The increasing birth rates are anticipated to drive the growth of the antipyretic drug for children market in the coming years. Birth rate refers to the number of live births per 1,000 people in a population annually. A rising birth rate can be attributed to better access to healthcare, improved economic conditions, and higher fertility rates in certain regions. An increasing birth rate can boost the demand for antipyretic drugs for children, as a larger number of infants and young children requires more medical attention, including fever management. For example, in September 2024, according to the Registry of Births, Deaths, and Marriages in Victoria, an Australia-based electronic resource, the number of births registered in Victoria rose from 7,689 in July 2024 to 7,994 in August 2024. Hence, rising birth rates are contributing to the growth of the antipyretic drug for children market.

Major companies operating in the antipyretic drugs for children market are concentrating on creating innovative drug formulations, such as medicine gummy bites that offer chewable, flavorful, and easy-to-administer dosage forms to enhance compliance and comfort for young patients. Medicine gummy bites are child-friendly chewable formulations containing a precisely measured dose of an antipyretic agent (such as acetaminophen), designed to mask unpleasant taste, ease swallowing, and simplify administration for caregivers while maintaining consistent therapeutic effects. For example, in October 2023, DrKids, a US-based pharmaceutical company, introduced an acetaminophen gummy bite, a child-friendly pain- and fever-relief option featuring a pre-measured dosing system for accurate administration, a palatable chewable gummy format that improves acceptance, and a convenient design that supports safe, stress-free dosing for parents.

Major companies operating in the antipyretic drugs for children market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, GlaxoSmithKline plc, Reckitt Benckiser Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Limited, Towa Pharmaceutical Co Ltd, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited.

North America was the largest region in the antipyretic drugs for children market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antipyretic drugs for children market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antipyretic drugs for children market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antipyretic drugs for children market by increasing the cost of imported active pharmaceutical ingredients, packaging materials, and manufacturing equipment. These cost pressures have most affected acetaminophen and ibuprofen segments and regions such as asia-pacific and north america, where a large share of pediatric drug manufacturing and sourcing occurs. Higher production costs have led to pricing pressures across syrup, tablet, and suppository dosage forms. However, tariffs have also encouraged local drug manufacturing and sourcing of ingredients, helping strengthen domestic supply chains and improve long-term availability.

The antipyretic drugs for children market research report is one of a series of new reports that provides antipyretic drugs for children market statistics, including antipyretic drugs for children industry global market size, regional shares, competitors with a antipyretic drugs for children market share, detailed antipyretic drugs for children market segments, market trends and opportunities, and any further data you may need to thrive in the antipyretic drugs for children industry. This antipyretic drugs for children market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antipyretic drugs for children are medicines used to decrease fever in children. They function by reducing the body's temperature through different mechanisms, such as blocking the production of substances that cause fever. These drugs help relieve discomfort and prevent issues related to high fever in children.

The primary drug categories of antipyretic medications for children include acetaminophen, ibuprofen, and others. Acetaminophen, also known as paracetamol, is an analgesic and antipyretic used to relieve pain and reduce fever, without exhibiting anti-inflammatory effects. It is available in different dosage forms such as tablets, syrups, suppositories, and more, suitable for various age groups, including newborns, infants, toddlers, and children.

The antipyretic drugs for children market consists of sales of acetaminophen (tylenol), ibuprofen (advil, motrin), and naproxen (aleve). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.